Phaseline

Companies › Tango Therapeutics

Tango Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TNG456
selective PRMT5 inhibitor
PRMT5Phase 1Non Small Cell Lung CancerMar 2027
RMC-9805
RAS(ON) G12D selective covalent inhibitor
KRASPhase 1PDACJun 2027
TNG462
Selective PRMT5 inhibitor
PRMT5Phase 1Locally Advanced Solid Tumor; PDACJun 2027
TNG260
CoREST inhibitor
–Phase 1Non Small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05887492TNG260Phase 1Non Small Cell Lung CancerOncologySep 2026
NCT06810544TNG456Phase 1Non Small Cell Lung CancerOncologyMar 2027
NCT05732831TNG462Phase 1Locally Advanced Solid TumorOncologyJun 2027
NCT06922591TNG462Phase 1PDACOncologyJun 2027
NCT06922591RMC-9805Phase 1PDACOncologyJun 2027

From the company's SEC filings

Cash and short-term investments of $978m on 2026-09-30; operating cash outflow about $162m a year; runway about 73 months at that burn, to Oct 2032

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 18 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PRMT5 (2) KRAS (1)

Companies with the same targets

Revolution Medicines Bristol-Myers Squibb Amgen TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bayer Novartis Astellas

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.